Cordant Inc’s Blueprint Medicines BPMC Stock Holding History

Cordant Inc’s Portfolio BPMC Stock Details BPMC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	–	Sell	-3	Closed	–	–	222
2022 Q1	$0	Buy	+3	New	+$215	﹤0.01%	1230

Other funds holding BPMC

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

CCM

Cadian Capital Management New York $821M AUM 14.36% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return

Cordant Inc's BPMC Position: Q2 2022 in Review

Cordant Inc sold out of Blueprint Medicines (BPMC) in Q2 2022, closing a stake of 3 shares.

Cordant Inc first reported a position in BPMC in Q1 2022 and held it in 1 quarter. The position peaked at $0 in Q1 2022. 237 funds tracked by Wall St. Rank hold BPMC as of Q2 2022.

Cordant Inc reported no remaining Blueprint Medicines position as of Q2 2022 after selling out during the quarter.
Cordant Inc sold 3 Blueprint Medicines shares in Q2 2022.
Cordant Inc first reported a position in Blueprint Medicines in Q1 2022 and held it in 1 quarter.
Cordant Inc's Blueprint Medicines position peaked at $0 in Q1 2022.
237 funds tracked by Wall St. Rank held Blueprint Medicines as of Q2 2022.

Based on Cordant Inc's 13F filing for Q2 2022, filed 17 Aug 2022.